Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gemina Laboratories Ltd (CSE: GLAB )

0.3900 +0.0500 (+14.71%)
Official Closing Price Updated: 3:58 PM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,700
Open 0.3950
Bid (Size) 0.3800 (500)
Ask (Size) 0.4000 (500)
Prev. Close 0.3400
Today's Range 0.3550 - 0.4400
52wk Range 0.2000 - 0.6000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gemina Laboratories Strategic Update
Via ACCESSWIRE
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire

Performance

YTD
-29.09%
-29.09%
1 Month
-26.42%
-26.42%
3 Month
-11.36%
-11.36%
6 Month
-25.00%
-25.00%
1 Year
-13.33%
-13.33%

More News

Read More
Gemina Laboratories Commences Trading on the OTCQB Market in the United States
Via ACCESSWIRE
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
From Virtual Investor Conferences
Via GlobeNewswire
Gemina Labs Announces Addition to its IP Portfolio
Via ACCESSWIRE
Gemina Laboratories to Participate in Poster Session at American Association of Clinical Chemistry Annual Scientific Meeting
Via ACCESSWIRE
Gemina Labs to Present at the Life Science Investor Forum June 20th
From Virtual Investor Conferences
Via GlobeNewswire
Gemina Laboratories Sign First Strategic License Agreement
Via ACCESSWIRE
Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships
Via ACCESSWIRE
Gemina Announces Closing of $910,000 Convertible Note Financing
Via ACCESSWIRE
Gemina's Recent Investment into RAPIvD Sees Immediate Progress
Via ACCESSWIRE
ReadyGo Diagnostics Initiates An Assay Development Contract With Gemina Laboratories For The Detection Of Dengue From Saliva Samples
Via Get News
Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose
Via ACCESSWIRE
Gemina Laboratories and ReadyGo Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in Saliva
Via ACCESSWIRE
Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement
Via ACCESSWIRE
Gemina Laboratories to Host Investor Webinar on March 30, 2023
Via ACCESSWIRE
Gemina Labs Appoints Diagnostic Strategist Martha Najib to the Board
Via ACCESSWIRE
Gemina Labs Announces Appointment of Healthcare Industry Leader Dr. Bola Grace to The Board of Directors
Via ACCESSWIRE
Gemina Labs Appoints Top Ranked UK Analyst and Scientist, Dr. Stefan Hamill as Vice President, Strategy
Via ACCESSWIRE
Gemina Labs Strategic Update: Respiratory Infections the Immediate Focus and New Strategic Partnerships on the Horizon
Via ACCESSWIRE
Gemina Labs Completes Influenza A/B Diagnostic Test Prototype
Via ACCESSWIRE
Gemina Labs Appoints Dr Michael Shannon as Chair of Clinical Advisory Board
Via ACCESSWIRE
Gemina Labs Announces Research Collaboration on Next Generation Biosensors
Via ACCESSWIRE
Gemina Labs Announces Strategic Stake in British Rapid Test Optimizer Rapivd Limited
Via ACCESSWIRE
Gemina Labs Enters into Licence and Manufacturing Agreements
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.